LAVA Therapeutics Analyst Ratings
LAVA Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/17/2023 | 322.54% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
08/23/2023 | 322.54% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
08/23/2023 | 322.54% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
06/15/2023 | 322.54% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
06/12/2023 | 533.8% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
06/09/2023 | 322.54% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
04/13/2023 | 533.8% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
02/17/2023 | 533.8% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
10/25/2022 | 533.8% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
09/27/2022 | 1871.83% | SVB Leerink | $25 → $28 | Maintains | Outperform |
09/15/2022 | 322.54% | JMP Securities | → $6 | Initiates Coverage On | → Market Outperform |
05/18/2022 | 1660.56% | SVB Leerink | $23 → $25 | Maintains | Outperform |
11/16/2021 | 1308.45% | SVB Leerink | $24 → $20 | Maintains | Outperform |
08/17/2021 | 1590.14% | SVB Leerink | $26 → $24 | Maintains | Outperform |
04/19/2021 | 1519.72% | Jefferies | → $23 | Initiates Coverage On | → Buy |
04/19/2021 | 1449.3% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
04/19/2021 | 1730.99% | SVB Leerink | → $26 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/17/2023 | 322.54% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
08/23/2023 | 322.54% | JMP 证券 | → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
08/23/2023 | 322.54% | HC Wainwright & Co. | 9 美元 → 6 美元 | 维护 | 买 |
06/15/2023 | 322.54% | JMP 证券 | → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
06/12/2023 | 533.8% | HC Wainwright & Co. | → 9 美元 | 重申 | 购买 → 购买 |
06/09/2023 | 322.54% | JMP 证券 | → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
04/13/2023 | 533.8% | HC Wainwright & Co. | → 9 美元 | 重申 | → 购买 |
02/17/2023 | 533.8% | HC Wainwright & Co. | → 9 美元 | 重申 | → 购买 |
10/25/2022 | 533.8% | HC Wainwright & Co. | → 9 美元 | 启动覆盖范围开启 | → 购买 |
09/27/2022 | 1871.83% | SVB Leerink | 25 美元 → 28 美元 | 维护 | 跑赢大盘 |
2022 年 9 月 15 日 | 322.54% | JMP 证券 | → 6 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
05/18/2022 | 1660.56% | SVB Leerink | 23 美元 → 25 美元 | 维护 | 跑赢大盘 |
11/16/2021 | 1308.45% | SVB Leerink | 24 美元 → 20 美元 | 维护 | 跑赢大盘 |
2021 年 8 月 17 日 | 1590.14% | SVB Leerink | 26 美元 → 24 美元 | 维护 | 跑赢大盘 |
2021 年 4 月 19 日 | 1519.72% | 杰富瑞集团 | → 23 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 4 月 19 日 | 1449.3% | 摩根大通 | → 22 美元 | 启动覆盖范围开启 | → 超重 |
2021 年 4 月 19 日 | 1730.99% | SVB Leerink | → 26 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for LAVA Therapeutics (LVTX)?
LAVA Therapeutics(LVTX)的目标价格是多少?
The latest price target for LAVA Therapeutics (NASDAQ: LVTX) was reported by HC Wainwright & Co. on November 17, 2023. The analyst firm set a price target for $6.00 expecting LVTX to rise to within 12 months (a possible 322.54% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月17日公布了LAVA Therapeutics(纳斯达克股票代码:LVTX)的最新目标股价。该分析公司将目标股价定为6.00美元,预计LVTX将在12个月内升至12个月内(可能上涨322.54%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for LAVA Therapeutics (LVTX)?
LAVA Therapeutics(LVTX)的最新分析师评级是多少?
The latest analyst rating for LAVA Therapeutics (NASDAQ: LVTX) was provided by HC Wainwright & Co., and LAVA Therapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了LAVA Therapeutics(纳斯达克股票代码:LVTX)的最新分析师评级,LAVA Therapeutics重申了其买入评级。
When is the next analyst rating going to be posted or updated for LAVA Therapeutics (LVTX)?
LAVA Therapeutics(LVTX)的下一次分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LAVA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LAVA Therapeutics was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与LAVA Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。LAVA Therapeutics的最新评级是在2023年11月17日公布的,因此您应该预计下一个评级将在2024年11月17日左右公布。
Is the Analyst Rating LAVA Therapeutics (LVTX) correct?
分析师对LAVA Therapeutics(LVTX)的评级正确吗?
While ratings are subjective and will change, the latest LAVA Therapeutics (LVTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price LAVA Therapeutics (LVTX) is trading at is $1.42, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但重申了最新的LAVA Therapeutics(LVTX)评级,目标股价为0.00美元至6.00美元。LAVA Therapeutics(LVTX)目前的交易价格为1.42美元,在分析师的预测区间内。